Chinese researchers have developed an advanced gene editing approach that successfully treats β-Thalassaemia, building on the first FDA-approved CRISPR therapy for sickle-cell anemia. The new system uses a protein that converts cytosine to thymine, avoiding the double-stranded breaks that cause problems in traditional CRISPR methods. This approach demonstrates the growing viability of gene editing technologies for treating genetic blood disorders.

The therapy works by reactivating the fetal version of a hemoglobin gene, which is normally shut off in adults but has higher oxygen affinity. In a clinical trial with five β-Thalassaemia patients, all achieved the trial's key success metric: going over six months without needing blood transfusions. Patients received edited blood stem cells, with careful screening to ensure no off-target edits occurred.

While the treatment shows promising results, researchers note the high cost due to complex cell culture and DNA sequencing procedures. Despite this expense, the success demonstrates gene editing's transition from experimental technology to practical therapy. This advancement opens new possibilities for treating genetic blood disorders using similar approaches targeting fetal gene reactivation.